Astellas Pharma
(OTC) ALPMY
Astellas Pharma Financials at a Glance
Market Cap
$26.05B
Revenue (TTM)
$2.27T
Net Income (TTM)
$309.12B
EPS (TTM)
$1.08
P/E Ratio
13.43
Dividend
$0.25
Beta (Volatility)
0.31 (Low)
Dividend
$0.25
Beta (Volatility)
0.31 (Low)
Price
$14.54
Volume
88,099
Open
$14.48
Price
$14.54
Volume
88,099
Open
$14.48
Previous Close
$14.54
Daily Range
$14.45 - $14.59
52-Week Range
$9.11 - $17.35
Dividend
$0.25
Beta (Volatility)
0.31 (Low)
Price
$14.54
Volume
88,099
Open
$14.48
Previous Close
$14.54
Daily Range
$14.45 - $14.59
52-Week Range
$9.11 - $17.35
ALPMY News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Astellas Pharma
Industry
Pharmaceuticals
Sector
Health CareEmployees
13,643
CEO
Naoki Okamura
Website
www.astellas.comHeadquarters
Tokyo, 103-8411, JP
ALPMY Financials
Key Financial Metrics (TTM)
Gross Margin
76%
Operating Margin
19%
Net Income Margin
14%
Return on Equity
18%
Return on Capital
17%
Return on Assets
8%
Earnings Yield
7.45%
Dividend Yield
1.73%
Payout Ratio
46.68%
Stock Overview
Market Cap
$26.05B
Shares Outstanding
1.79B
Volume
88.10K
Avg. Volume
158.99K
Financials (TTM)
Gross Profit
$1.69T
Operating Income
$445.01B
EBITDA
$651.34B
Operating Cash Flow
$600.40B
Capital Expenditure
$61.20B
Free Cash Flow
$539.20B
Cash & ST Invst.
$282.83B
Total Debt
$247.02B
Astellas Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$647.49B
+41.0%
Gross Profit
$457.56B
+19.6%
Gross Margin
70.67%
N/A
Market Cap
$26.05B
N/A
Market Cap/Employee
$1.77M
N/A
Employees
14,754
N/A
Net Income
$57.97B
-22.6%
EBITDA
$52.63B
-151.7%
Quarterly Fundamentals
Net Cash
$35.81B
+105.8%
Accounts Receivable
$765.07B
+21.0%
Inventory
$332.45B
+11.8%
Long Term Debt
$321.39B
-43.1%
Short Term Debt
$247.02B
-7.3%
Return on Assets
8.17%
N/A
Return on Invested Capital
17.24%
N/A
Free Cash Flow
$191.01B
+109.0%
Operating Cash Flow
$207.50B
+105.3%